Close Menu

NEW YORK (GenomeWeb) – Cancer Genetics reported on Tuesday that its fourth quarter revenues fell 9 percent year over year, partially due to the impact on its clinical services business unit from the adoption of new revenues recognition standards at the beginning of 2018.

For the three months ended Dec. 31, 2018, the firm reported total revenues of $6.8 million, down from $7.5 million in the fourth quarter of 2017. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.